9 resultater
FIELD OF THE INVENTION
The present invention relates to quinoline derivatives and to the use thereof in therapy. More particularly, the present invention relates to quinoline derivatives for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke,
This invention relates to pyridazinedione compounds useful in the treatment of neurological disorders generally in mammals such as man. More specifically, the compounds are useful in the treatment of strokes and/or other neuro-degenerative disorders such as hypoglycemia, cerebral palsy, transient
The present application relates to new uses of 5-HT.sub.6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT.sub.6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with a second therapeutic
This application is a 371 of International Application No. PCT/EP2008/067225, filed 10 Dec. 2008, which claims the priority of GB Application Nos. 072428.1, filed 12 Dec. 2007, and 0724285.2, filed 12 Dec. 2007, which are incorporated herein in their entireties.
The present application relates to
FIELD OF THE INVENTION
The present invention relates to quinoline derivatives and to the use thereof in therapy. More particularly, the present invention relates to quinoline derivatives for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke,
BACKGROUND OF THE INVENTION
Recent studies with the selective 5-HT.sub.1A antagonist WAY-100635 have confirmed a role for 5-HT.sub.1A receptors in learning and memory. Carli et al. (Neuropharmacology (1999), 38(8), 1165-1173) demonstrated that WAY-100635 prevented the impairment of spatial learning
FIELD OF THE INVENTION
This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,
FIELD OF THE INVENTION
This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,
FIELD OF THE INVENTION
The present invention relates to pharmaceutical compositions comprising as active ingredients compounds that act as neuroprotective iron chelators and are suitable for the treatment of neurodegenerative disorders such as Parkinson's disease, Alzheimer-type dementia and stroke.